Portfolio Managers Andy Acker and Agustin Mohedas explain why shares of companies delivering next-generation therapies for inflammation and immunology (I&I) disorders could have plenty of room to run.
Passive funds continue to dominate
First large drop since financial crisis
Versus 36% of active equity managers
UK-focused funds shed £448m
Carries own set of risks